Inhibitor Therapeutics INTI
OTC INTI
$0.10 +0.00 (+0.00%)
At close: Sep 29, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Long-Term Debt Repayments (2014 - 2023)

Updated

Inhibitor Therapeutics (INTI) recorded Long-Term Debt Repayments of $411,000 in FY2023.

Analysis

Inhibitor Therapeutics (INTI) Long-Term Debt Repayments (2014 - 2023) Analysis & Trends

  • The FY2023 figure is the lowest annual Long-Term Debt Repayments since FY2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.00 Mn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 2.00 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 5.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -2.45 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 17.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Inhibitor Therapeutics 17.38 Mn 17.38 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 411,000.00
Dec 31, 2014 41,920.00
API Access

Inhibitor Therapeutics Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=INTI&period=max&api_key=YOUR_API_KEY